Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer

Taiseer Al-Rajabi; Jarushka Naidoo; Jun Zhang

doi:10.3389/fonc.2023.1277542

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer

Front Oncol. 2023 Sep 8:13:1277542. doi: 10.3389/fonc.2023.1277542. eCollection 2023.

Authors

Taiseer Al-Rajabi¹, Jarushka Naidoo², Jun Zhang^{3

4}

Affiliations

¹ University of Kansas, Lawrence, KS, United States.
² Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD, United States.
³ Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
⁴ Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, United States.

No abstract available

Keywords: cancer immunotherapy; immune checkpoint inhibitors; immune related adverse effects (irAEs); immunotherapy; non-small cell lung cancer (NSCLC).

Publication types

Editorial